Press Release: Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer
Propella Therapeutics Inc., a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care.